Functional Connectivity and Predictors of Affective Aprosodia Intervention in Subacute Right Hemisphere Stroke

March 19, 2024 updated by: Johns Hopkins University
This study is an investigation of a behavioral speech and language treatment for emotional prosody recognition and production deficits in subacute right hemisphere stroke.

Study Overview

Detailed Description

The phrase, "it's not what you say, but how you say it" neatly sums up prosody - the changes to one's tone of voice that transmit meaning. Changes to speech rate, rhythm, volume, and pitch to convey emotion fall into the category of affective, or emotional, prosody. That is, the changes made to the voice to express feelings, such as happy or sad.

Following damage to the right side of the brain, such as in stroke, difficulties in affective prosody understanding and use have been observed. These findings have led researchers to view the right hemisphere as playing a critical role for emotional prosody. Affective prosody difficulties do not always spontaneously improve after acute right hemisphere stroke, and only a few evidenced-based treatments are available for these individuals. It is also understood that affective prosody difficulties can negatively impact social interactions and relationships, including those who care for individuals with emotional prosody difficulties. With miscommunication frequently occurring between those living with affective prosody disorders and those with whom these people interact, the risk of reduced quality of life and social isolation is possible and could be related to poorer health outcomes. Not only might there be personal burdens associated with poor management of communication difficulties in right hemisphere stroke and dementia, but there might also be economic burdens as well. In addition to counseling caregivers, family, and friends about the communication changes of loved ones, more evidenced-based speech and language treatment options are needed for those living with affective prosody disorders.

Cognitive-Linguistic and Speech-Language Assessment: During baseline testing, detailed speech-language and cognitive-communication behavioral testing will occur, focusing on aprosodia, awareness, motor speech, attention, verbal working memory, executive function, discourse, social participation, and emotion. Detailed testing focusing on aprosodia will occur after each Intervention Phase.

Functional near-infrared spectroscopy: Resting state functional connectivity as measured via functional near-infrared spectroscopy (fNIRS) will be assessed at Baseline, Post Phase I, and Post Phase II testing time points to track longitudinal change in functional connectivity patterns associated with targeted aprosodia intervention.

Aprosodia Intervention Phase: The aprosodia intervention will target receptive and expressive prosody over the course of four (4) weeks (12 sessions total). The receptive prosody intervention phase will occur for two weeks (6 sessions total, 3 sessions/week), and the expressive prosody intervention phase will occur for two weeks (6 sessions total, 3 sessions/week). Within each phase, the types of cues participants receive will also vary. Half of the expressive prosody intervention phase will use explicit cues (3 sessions total, 1 week), and the other half of the expressive prosody intervention phase will use implicit cues (3 sessions total, 1 week). This same setup for expressive prosody intervention phase will be used in the receptive prosody intervention phase. In addition to these implicit and explicit cues, expressive prosody intervention will also include feedback to increase awareness.

No-Intervention Phase: Participants will meet study personnel with the same frequency and duration (3 sessions/week, ~1 hour/session) during the No-Intervention Phase as during REACT. Sessions will comprise conversation about current events, recovery progress (including speech therapy goals targeted in outside intervention [if relevant]), hobbies, and other similar topics.

Study Type

Interventional

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Maryland
      • Baltimore, Maryland, United States, 21287
        • Johns Hopkins School of Medicine

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 89 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Ischemic stroke to the right cerebral hemisphere
  • No history of other significant neurological disease or injury affecting the brain (excluding prior lacunar stroke, asymptomatic stroke, or TIA)
  • Proficient speaker of English prior to stroke per self-report
  • Capable of providing informed consent or indicating another to provide informed consent
  • Ages 18-89
  • Demonstration of receptive and/or expressive aprosodia on standardized measures of aprosodia
  • Does not have severe cognitive impairment (MoCA > 9)
  • Is not severely depressed (PHQ-9 < 20)
  • Does not have more than mild motor speech impairment (ASRS < 16 and Dysarthria severity < 3)
  • Normal or corrected-to-normal hearing and vision via screening tasks and self-report
  • Medically stable
  • Not taking any medications that may interfere with prosody processing
  • Participation in speech therapy not targeting aprosodia

Exclusion Criteria:

  • Ischemic stroke outside the right hemisphere or primary hemorrhagic stroke in the right hemisphere
  • History of symptomatic stroke or significant neurological disease or injury affecting the brain
  • No proficiency in English based on self-report
  • Unable to provide informed consent or to indicate another to provide informed consent
  • Children < 18 and adults 90+ years
  • No demonstration of expressive or receptive aprosodia
  • Severe cognitive-linguistic impairment (MoCA < 16)
  • Severe depression (PHQ-9 > 19)
  • More than mild motor speech impairment (ASRS > 15 + Dysarthria severity < 2)
  • Uncorrected hearing/vision loss via screening tasks and self-report
  • Not medically stable
  • Reported medication use that may interfere with prosody processing
  • Participating in outside speech therapy targeting aprosodia

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Explicit Expressive Prosody Intervention
Explicit cues will be provided to help participants improve expression of targeted affective prosody.
Intervention will focus on improving participants' use and understanding of emotional prosody using implicit and explicit cues, biofeedback, modeling, and feedback.
Experimental: Implicit Expressive Prosody Intervention
Implicit cues will be provided to help participants improve expression of targeted affective prosody.
Intervention will focus on improving participants' use and understanding of emotional prosody using implicit and explicit cues, biofeedback, modeling, and feedback.
Experimental: Explicit Receptive Prosody Intervention
Explicit cues will be provided to help participants improve recognition of targeted affective prosody.
Intervention will focus on improving participants' use and understanding of emotional prosody using implicit and explicit cues, biofeedback, modeling, and feedback.
Experimental: Implicit Receptive Prosody Intervention
Implicit cues will be provided to help participants improve recognition of targeted affective prosody.
Intervention will focus on improving participants' use and understanding of emotional prosody using implicit and explicit cues, biofeedback, modeling, and feedback.
Active Comparator: No-Intervention
Sessions will comprise conversation about current events, recovery progress (including speech therapy goals targeted in outside intervention [if relevant]), hobbies, and other similar topics.
Sessions will comprise conversation about current events, recovery progress (including speech therapy goals targeted in outside intervention [if relevant]), hobbies, and other similar topics.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in accuracy on affective prosody expression following aprosodia intervention compared to spontaneous recovery
Time Frame: Baseline, 1 week after Phase I Intervention, 1 week after Phase II Intervention
Change in accuracy of participants' ability to express affective prosody on sentence lists (list score range 0-45), with increasing accuracy indicating better outcome.
Baseline, 1 week after Phase I Intervention, 1 week after Phase II Intervention
Change in accuracy on affective prosody recognition following aprosodia intervention compared to spontaneous recovery
Time Frame: Baseline, 1 week after Phase I Intervention, 1 week after Phase II Intervention
Change in accuracy of participants' ability to express affective prosody on sentence lists (list score range 0-45), with increasing accuracy indicating better outcome.
Baseline, 1 week after Phase I Intervention, 1 week after Phase II Intervention
Change in accuracy on standardized contextual measures of affective prosody expression
Time Frame: Baseline, 1 week after Phase I Intervention, 1 week after Phase II Intervention
Change in accuracy on the Montreal Evaluation of Communication (score range 0-18), with increasing score indicating better outcome.
Baseline, 1 week after Phase I Intervention, 1 week after Phase II Intervention
Change in accuracy on standardized contextualized measures of affective prosody recognition
Time Frame: 1 week after Phase I Intervention, 1 week after Phase II Intervention
Change in accuracy on The Awareness of Social Inference Test (score range 0-24, with increasing score indicating better outcome.
1 week after Phase I Intervention, 1 week after Phase II Intervention
Change in resting state functional connectivity
Time Frame: Baseline, 1 week after Phase I Intervention, 1 week after Phase II Intervention
Differences in resting state functional connectivity patterns within prosody-specific regions of interest and left homologues (connectivity association range 0-0.99), with increasing association values indicating stronger connectivity
Baseline, 1 week after Phase I Intervention, 1 week after Phase II Intervention
Behavioral and neurological predictors of aprosodia intervention outcomes
Time Frame: Baseline, 1 week after Phase I or Phase II Intervention
Scores on baseline cognitive-linguistic assessments and percent damage to lesioned regions of interest, larger beta coefficients indicating a stronger relationship between predictor (baseline behavioral and neurological data) and predicted (prosody accuracy) variables.
Baseline, 1 week after Phase I or Phase II Intervention

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in standardized acoustic features (rate, frequency, intensity, rhythm), on standardized measures of prosody expression
Time Frame: Baseline, 1 week after Phase I Intervention, 1 week after Phase II Intervention
Change in z-scored acoustic features on the Montreal Evaluation of Communication expression subtest, with scores closer to zero indicating better outcome.
Baseline, 1 week after Phase I Intervention, 1 week after Phase II Intervention

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in accuracy on standardized measures of affective prosody expression
Time Frame: Baseline, 1 week after Phase I Intervention, 1 week after Phase II Intervention, 4 weeks after Phase II Intervention
Change in accuracy on the Montreal Evaluation of Communication (score range 0-18), with increasing score indicating better outcome.
Baseline, 1 week after Phase I Intervention, 1 week after Phase II Intervention, 4 weeks after Phase II Intervention
Change in accuracy on standardized measures of affective prosody recognition
Time Frame: Baseline, 1 week after Phase I Intervention, 1 week after Phase II Intervention, 4 weeks after Phase II Intervention
Change in accuracy on the Montreal Evaluation of Communication (score range 0-12) and The Awareness of Social Inference Test (score range 0-24, with increasing score indicating better outcome.
Baseline, 1 week after Phase I Intervention, 1 week after Phase II Intervention, 4 weeks after Phase II Intervention
Change in accuracy on affective prosody expression
Time Frame: Baseline, 1 week after Phase I Intervention, 1 week after Phase II Intervention, 4 weeks after Phase II Intervention
Change in accuracy of participants' ability to express affective prosody on sentence lists (list score range 0-45), with increasing accuracy indicating better outcome.
Baseline, 1 week after Phase I Intervention, 1 week after Phase II Intervention, 4 weeks after Phase II Intervention
Change in accuracy on affective prosody recognition
Time Frame: Baseline, 1 week after Phase I Intervention, 1 week after Phase II Intervention, 4 weeks after Phase II Intervention
Change in accuracy of participants' ability to recognize affective prosody on sentence lists (list score range 0-45), with increasing accuracy indicating better outcome.
Baseline, 1 week after Phase I Intervention, 1 week after Phase II Intervention, 4 weeks after Phase II Intervention
Change in report of social participation
Time Frame: Baseline, 1 week after Phase I Intervention, 1 week after Phase II Intervention, 4 weeks after Phase II Intervention
Change in social participation as measure on the Sydney Psychosocial Reintegration Scale Version 2 (score range 0-48), with increasing score indicating worse outcome.
Baseline, 1 week after Phase I Intervention, 1 week after Phase II Intervention, 4 weeks after Phase II Intervention
Change in resting state functional connectivity
Time Frame: Baseline, 1 week after Phase I Intervention, 1 week after Phase II Intervention, 4 weeks after Phase II Intervention
Differences in resting state functional connectivity patterns within prosody-specific regions of interest and left homologues (connectivity association range 0-0.99), with increasing association values indicating stronger connectivity
Baseline, 1 week after Phase I Intervention, 1 week after Phase II Intervention, 4 weeks after Phase II Intervention
Change in standardized acoustic features (rate, frequency, intensity, rhythm), on standardized measures of prosody expression
Time Frame: Baseline, 1 week after Phase I Intervention, 1 week after Phase II Intervention, 4 weeks after Phase II Intervention
Change in z-scored acoustic features on the MEC-expression subtest, with scores closer to zero indicating better outcome.
Baseline, 1 week after Phase I Intervention, 1 week after Phase II Intervention, 4 weeks after Phase II Intervention

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Argye E Hillis, MD, MA, Johns Hopkins University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 1, 2021

Primary Completion (Actual)

March 19, 2024

Study Completion (Actual)

March 19, 2024

Study Registration Dates

First Submitted

September 18, 2020

First Submitted That Met QC Criteria

September 29, 2020

First Posted (Actual)

October 5, 2020

Study Record Updates

Last Update Posted (Actual)

March 20, 2024

Last Update Submitted That Met QC Criteria

March 19, 2024

Last Verified

March 1, 2024

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Right Hemispheric Stroke

Clinical Trials on Aprosodia Intervention

Subscribe